- HOPE-NMP is the first randomised controlled trial investigating the effects of end-ischemic HOPE and end-ischemic NMP compared to CCS in a multi-centre prospective randomised controlled clinical trial (RCT) using ECD liver grafts in DBD liver-transplantation (NCT04644744).
- HOPE-NMP focuses on patients solely receiving ECD-allografts, a population we anticipate the best cost/benefit ratio from the utilization of HOPE.
- HOPE-NMP focuses on donation after brain death, the most frequent source of ECD-allografts in Europe.
- Multi-centric design, currently 3 centres (Charité Universitätsmedizin Berlin, University Hospital Heidelberg, University Hospital Hannover)
- Principal Investigator (Charité Universitätsmedizin Berlin): Georg Lurje, M.D.
- Co-Principal Investigator (Charité Universitätsmedizin Berlin): Johann Pratschke, M.D.
- Local Investigator (University Hospital Heidelberg): Arianeb Mehrabi, M.D.
- Local Investigator (University Hospital Hannover): Florian Vondran, M.D.
- Local Investigator (University Hospital Aachen): Zoltan Czigany, M.D. (in preparation)
HOPE-NMP 